JMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Ocular Therapeutix (OCUL) but lowers the price target from $24 to $22.

May 08, 2024 | 6:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Ocular Therapeutix but lowers the price target from $24 to $22.
While the reduction in price target could suggest a slight adjustment in valuation expectations, the maintenance of a Market Outperform rating indicates a continued positive outlook on the company's performance. This mixed signal could lead to neutral short-term price movement as investors weigh the lowered price target against the reaffirmed positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100